Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISRG's Cash to Debt is ranked higher than
84% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ISRG: No Debt )
ISRG' s 10-Year Cash to Debt Range
Min: 12.85   Max: No Debt
Current: No Debt

Equity to Asset 0.87
ISRG's Equity to Asset is ranked higher than
93% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. ISRG: 0.87 )
ISRG' s 10-Year Equity to Asset Range
Min: 0.7   Max: 0.9
Current: 0.87

0.7
0.9
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
87% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. ISRG: No Debt )
ISRG' s 10-Year Interest Coverage Range
Min: 232.79   Max: 9999.99
Current: No Debt

232.79
9999.99
F-Score: 4
Z-Score: 18.25
M-Score: -3.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 37.64
ISRG's Operating margin (%) is ranked higher than
98% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. ISRG: 37.64 )
ISRG' s 10-Year Operating margin (%) Range
Min: -191.81   Max: 40.3
Current: 37.64

-191.81
40.3
Net-margin (%) 29.62
ISRG's Net-margin (%) is ranked higher than
97% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. ISRG: 29.62 )
ISRG' s 10-Year Net-margin (%) Range
Min: -180.68   Max: 41.41
Current: 29.62

-180.68
41.41
ROE (%) 19.16
ISRG's ROE (%) is ranked higher than
93% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ISRG: 19.16 )
ISRG' s 10-Year ROE (%) Range
Min: -142.95   Max: 21.27
Current: 19.16

-142.95
21.27
ROA (%) 16.99
ISRG's ROA (%) is ranked higher than
96% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. ISRG: 16.99 )
ISRG' s 10-Year ROA (%) Range
Min: -104.53   Max: 18.77
Current: 16.99

-104.53
18.77
ROC (Joel Greenblatt) (%) 186.18
ISRG's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. ISRG: 186.18 )
ISRG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -721.63   Max: 221.49
Current: 186.18

-721.63
221.49
Revenue Growth (%) 17.20
ISRG's Revenue Growth (%) is ranked higher than
92% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ISRG: 17.20 )
ISRG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 57.1
Current: 17.2

0
57.1
EBITDA Growth (%) 15.80
ISRG's EBITDA Growth (%) is ranked higher than
85% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. ISRG: 15.80 )
ISRG' s 10-Year EBITDA Growth (%) Range
Min: -62.7   Max: 321.3
Current: 15.8

-62.7
321.3
EPS Growth (%) 20.90
ISRG's EPS Growth (%) is ranked higher than
87% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. ISRG: 20.90 )
ISRG' s 10-Year EPS Growth (%) Range
Min: -61.5   Max: 76.8
Current: 20.9

-61.5
76.8
» ISRG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

ISRG Guru Trades in Q3 2013

Robert Olstein 11,000 sh (New)
John Burbank 72,896 sh (New)
Steven Cohen 369,528 sh (+76248.8%)
Joel Greenblatt 25,743 sh (+1203.44%)
Ray Dalio 35,798 sh (+245.57%)
Jim Simons 455,570 sh (+97.33%)
Paul Tudor Jones 1,000 sh (+42.86%)
Frank Sands 1,639,948 sh (+30.83%)
Ronald Muhlenkamp Sold Out
Steve Mandel Sold Out
Jeremy Grantham 34,789 sh (-15.43%)
Ron Baron 95,060 sh (-29.83%)
Andreas Halvorsen 210,426 sh (-87.69%)
» More
Q4 2013

ISRG Guru Trades in Q4 2013

Louis Moore Bacon 15,000 sh (New)
RS Investment Management 301,632 sh (New)
Lee Ainslie 91,500 sh (New)
Frank Sands 2,137,990 sh (+30.37%)
Paul Tudor Jones 1,222 sh (+22.2%)
Robert Olstein 13,000 sh (+18.18%)
Ray Dalio 39,898 sh (+11.45%)
Andreas Halvorsen Sold Out
John Burbank Sold Out
Jeremy Grantham 32,071 sh (-7.81%)
Ron Baron 60,000 sh (-36.88%)
Jim Simons 208,720 sh (-54.18%)
Joel Greenblatt 11,086 sh (-56.94%)
Steven Cohen 1,600 sh (-99.57%)
» More
Q1 2014

ISRG Guru Trades in Q1 2014

Steven Cohen 29,761 sh (+1760.06%)
Jeremy Grantham 52,332 sh (+63.18%)
Frank Sands 2,192,223 sh (+2.54%)
Lee Ainslie Sold Out
Ron Baron Sold Out
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Robert Olstein 12,000 sh (-7.69%)
Joel Greenblatt 8,501 sh (-23.32%)
RS Investment Management 227,469 sh (-24.59%)
Jim Simons 108,500 sh (-48.02%)
Ray Dalio 3,080 sh (-92.28%)
» More
Q2 2014

ISRG Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 161,350 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Intuitive Surgical Inc

Baron Funds Comments on Intuitive Surgical - May 05, 2014

We sold out of the last of long-term holding Intuitive Surgical, Inc. (ISRG) Intuitive was one of the great investments in the Fund's history, but we let go of the last remnants of our position as the stock rebounded, and we felt uncertain about the device's utility in some of its new general surgery applications. Intuitive also has a $16 billion market cap on sale (it was $350 million on purchase!), and we need to be cognizant of market cap in our portfolio construction.





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Intuitive Surgical Inc. - Nov 21, 2013

Intuitive Surgical, Inc. (ISRG), which sells the da Vinci robotic surgical systems, fell 25.7% in the quarter when results fell short of expectations as growth in procedures slowed and unit placements declined. Hospital admissions have been weak and negative publicity affected the amount of procedures performed. We reduced our position in the stock by half this year, but now believe the stock is oversold and too cheap.

From Ron Baron’s Baron Funds third quarter 2013 report.


Check out Ron Baron latest stock trades

Baron Funds Comments on Intuitive Surgical Inc. - Nov 06, 2013

Intuitive Surgical, Inc. (ISRG) sells the 'da Vinci' robotic surgical system. The company's recent results fell short of expectations because of a slowdown in domestic benign gynecological procedures using da Vinci devices. This, in turn, led to slower than expected overall procedure growth and systems sales; management lowered its full year 2013 guidance as a result. After recognizing significant profits, we trimmed our position in the stock earlier this year because of concerns about the impact that increased focus on cost containment in the healthcare system might have on the company's long- term growth prospects. We continue to own a small position in the Fund.

From Ron Baron's Baron Funds third quarter 2013 report.


Check out Ron Baron latest stock trades

Baron Funds Comments on Intuitive Surgical Inc. - Dec 06, 2012

Intuitive Surgical, Inc. (ISRG) manufactures the da Vinci surgical system, which is used by surgeons to perform various 'robotic-assisted' procedures with improved clinical results, smaller incisions and faster recoveries for patients. In July, the company reported slightly lower-than-expected growth in procedures using the da Vinci systems. We believe the company has multiple long-term growth drivers still in place, including emerging procedures in general surgery and geographic expansion into Japan.

From Baron Funds’ third quarter commentary.


Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Baron Funds Comments on Intuitive Surgical
We sold out of the last of long-term holding Intuitive Surgical, Inc. (ISRG) Intuitive was one of the great investments in the Fund's history, but we let go of the last remnants of our position as the stock rebounded, and we felt uncertain about the device's utility in some of its new general surgery applications. Intuitive also has a $16 billion market cap on sale (it was $350 million on purchase!), and we need to be cognizant of market cap in our portfolio construction. Read more...
Viking Global Investors’ Impact Selling
The stocks bought by Andreas Halvorsen, co-founder and CEO of Viking Global Investors, averaged a return of 23.28% over 12 months, according to the GuruFocus Score Board of Gurus. Andreas Halvorsen’s recently updated portfolio shows 59 stocks, 24 of them new, with a total value of $18.11 billion and a quarter-over-quarter turnover of 33%. The hedge fund portfolio is currently weighted with the consumer cyclical sector at 26.4%, healthcare at 21.9% and financial services at 17.6%. Read more...
Baron Funds Comments on Intuitive Surgical Inc.
Intuitive Surgical, Inc. (ISRG), which sells the da Vinci robotic surgical systems, fell 25.7% in the quarter when results fell short of expectations as growth in procedures slowed and unit placements declined. Hospital admissions have been weak and negative publicity affected the amount of procedures performed. We reduced our position in the stock by half this year, but now believe the stock is oversold and too cheap. Read more...
Baron Funds Comments on Intuitive Surgical Inc.
Intuitive Surgical, Inc. (ISRG) sells the 'da Vinci' robotic surgical system. The company's recent results fell short of expectations because of a slowdown in domestic benign gynecological procedures using da Vinci devices. This, in turn, led to slower than expected overall procedure growth and systems sales; management lowered its full year 2013 guidance as a result. After recognizing significant profits, we trimmed our position in the stock earlier this year because of concerns about the impact that increased focus on cost containment in the healthcare system might have on the company's long- term growth prospects. We continue to own a small position in the Fund. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.00
ISRG's P/E(ttm) is ranked higher than
77% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.10 vs. ISRG: 29.00 )
ISRG' s 10-Year P/E(ttm) Range
Min: 17.79   Max: 207.43
Current: 29

17.79
207.43
P/B 4.10
ISRG's P/B is ranked higher than
65% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. ISRG: 4.10 )
ISRG' s 10-Year P/B Range
Min: 1.8   Max: 15.72
Current: 4.1

1.8
15.72
P/S 7.20
ISRG's P/S is ranked higher than
55% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ISRG: 7.20 )
ISRG' s 10-Year P/S Range
Min: 3.32   Max: 24.31
Current: 7.2

3.32
24.31
PFCF 22.40
ISRG's PFCF is ranked higher than
88% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 81.48 vs. ISRG: 22.40 )
ISRG' s 10-Year PFCF Range
Min: 18.4   Max: 506.71
Current: 22.4

18.4
506.71
EV-to-EBIT 19.98
ISRG's EV-to-EBIT is ranked higher than
80% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. ISRG: 19.98 )
ISRG' s 10-Year EV-to-EBIT Range
Min: 10.2   Max: 244.8
Current: 19.98

10.2
244.8
PEG 1.30
ISRG's PEG is ranked higher than
94% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.00 vs. ISRG: 1.30 )
ISRG' s 10-Year PEG Range
Min: 0.17   Max: 1.75
Current: 1.3

0.17
1.75
Shiller P/E 33.70
ISRG's Shiller P/E is ranked higher than
86% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISRG: 33.70 )
ISRG' s 10-Year Shiller P/E Range
Min: 30.83   Max: 740.63
Current: 33.7

30.83
740.63
Current Ratio 4.52
ISRG's Current Ratio is ranked higher than
86% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ISRG: 4.52 )
ISRG' s 10-Year Current Ratio Range
Min: 2.07   Max: 7.43
Current: 4.52

2.07
7.43
Quick Ratio 4.12
ISRG's Quick Ratio is ranked higher than
87% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. ISRG: 4.12 )
ISRG' s 10-Year Quick Ratio Range
Min: 1.72   Max: 7.07
Current: 4.12

1.72
7.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.39
ISRG's Price/Net Cash is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISRG: 14.39 )
ISRG' s 10-Year Price/Net Cash Range
Min: 2.88   Max: 333.4
Current: 14.39

2.88
333.4
Price/Net Current Asset Value 11.36
ISRG's Price/Net Current Asset Value is ranked higher than
87% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISRG: 11.36 )
ISRG' s 10-Year Price/Net Current Asset Value Range
Min: 2.43   Max: 35.43
Current: 11.36

2.43
35.43
Price/Tangible Book 4.33
ISRG's Price/Tangible Book is ranked higher than
74% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.62 vs. ISRG: 4.33 )
ISRG' s 10-Year Price/Tangible Book Range
Min: 2.05   Max: 16.35
Current: 4.33

2.05
16.35
Price/DCF (Projected) 1.41
ISRG's Price/DCF (Projected) is ranked higher than
89% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.59 vs. ISRG: 1.41 )
ISRG' s 10-Year Price/DCF (Projected) Range
Min: 1.46   Max: 14.73
Current: 1.41

1.46
14.73
Price/Median PS Value 0.71
ISRG's Price/Median PS Value is ranked higher than
92% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ISRG: 0.71 )
ISRG' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.08
Current: 0.71

0.3
2.08
Price/Peter Lynch Fair Value 1.32
ISRG's Price/Peter Lynch Fair Value is ranked higher than
96% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISRG: 1.32 )
ISRG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.81   Max: 3.95
Current: 1.32

0.81
3.95
Price/Graham Number 2.32
ISRG's Price/Graham Number is ranked higher than
83% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.49 vs. ISRG: 2.32 )
ISRG' s 10-Year Price/Graham Number Range
Min: 1.76   Max: 7.88
Current: 2.32

1.76
7.88
Earnings Yield (Greenblatt) 5.00
ISRG's Earnings Yield (Greenblatt) is ranked higher than
68% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. ISRG: 5.00 )
ISRG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 9.8
Current: 5

0.4
9.8
Forward Rate of Return (Yacktman) 24.54
ISRG's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 257 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. ISRG: 24.54 )
ISRG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.6   Max: 141.4
Current: 24.54

-2.6
141.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:IUI1.Germany
Intuitive Surgical, Inc., is a Delaware corporation founded in 1995. The Company designs, manufactures and markets da Vinci Surgical Systems, EndoWrist instruments, and surgical accessories. A da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a high performance vision system. The da Vinci Surgical System translates a surgeon's natural hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions, or ports. The da Vinci Surgical System is designed to provide its operating surgeon with intuitive control, range of motion, fine tissue manipulation capability and 3-D, High-Definition vision while simultaneously allowing the surgeon to work through the small ports of MIS. The Company manufactures its da Vinci Surgical Systems at its facility in Sunnyvale, California. It manufactures its EndoWrist instruments at its Sunnyvale facility and Mexicali, Mexico facility. The Company considers its main competition to be existing open surgery, conventional MIS, drug therapies, radiation treatment and emerging interventional surgical approaches. The Company faces competition from several companies that are developing new approaches and products for the MIS market. The Company's products and operations are subject to extensive and rigorous regulation by the FDA, the State of California and countries or regions in which it market its products.
» More Articles for ISRG

Headlines

Articles On GuruFocus.com
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows May 08 2014 
Baron Funds Comments on Intuitive Surgical May 05 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows May 01 2014 
5 Depressed Companies Ready for a Rebound - Worthy of a December Buy! Dec 13 2013 
Viking Global Investors’ Impact Selling Nov 29 2013 
Baron Funds Comments on Intuitive Surgical Inc. Nov 21 2013 
John Burbank's Top 10 Third Quarter Buys Nov 14 2013 
Baron Funds Comments on Intuitive Surgical Inc. Nov 06 2013 
5 Guru Stocks Near 52 Week Lows Nov 04 2013 
Guru Stocks at 52-Week Lows: IBM, EXC, BSMX, ISRG, DO Oct 26 2013 


More From Other Websites
Study: Women More Satisfied With da Vinci(R) Robotic-Assisted Hysterectomy Than Other Surgical... Jul 21 2014
Study: Women More Satisfied With da Vinci(R) Robotic-Assisted Hysterectomy Than Other Surgical... Jul 21 2014
Intuitive Surgical Exec: Here Is Why Robotic Surgery Is Useful Jul 17 2014
Intuitive Surgical Reports New Employee Option Grants for July 2014 Jul 14 2014
Intuitive Surgical Reports New Employee Option Grants for July 2014 Jul 14 2014
Memories Of March Return As Momentum Stocks Hit Hard Jul 08 2014
Intuitive Surgical to Begin Direct Sales of da Vinci(R) Surgical Systems in Japan Jul 01 2014
Intuitive Surgical's New da Vinci Robot Gets CE Mark Jun 26 2014
Intuitive Surgical Receives CE Mark for the da Vinci(R) Xi(TM) Surgical System Jun 25 2014
[video] S&P sets record high Jun 24 2014
Intuitive Surgical, Inc. Second Quarter, 2014 Earnings Conference Call Jun 16 2014
Intuitive Surgical Reports New Employee Option Grants for June 2014 Jun 12 2014
Intuitive Wins Trial, Defeats Negligent Training Claims Jun 10 2014
Intuitive Surgical Sponsors New Women's Cancer Research Database in Collaboration With the Society... Jun 09 2014
How Titan Medical Is Going To Revolutionize The Surgical Robotics Industry May 29 2014
Intuitive Surgical: New Products Offer Little Help As Future Uncertainties Remain May 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide